• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Hovione Expands Production At East Windsor, New Jersey, Manufacturing Campus

Hovione plans to operate a commercial-scale, state-of-the-art, “continuous manufacturing” facility as part of an agreement with Vertex Pharmaceuticals in East Windsor, New Jersey. The facility, which should be completed by the end of 2017, will support future manufacturing of Vertex's approved medicines.

According to the firm, “continuous manufacturing represents an innovative shift from the traditional multi-step, multi-location batch production process, which can take up to four weeks or more to make commercial-ready medicines. With continuous manufacturing, raw materials used to produce oral medicines (tablets) are fed into a single, continuously running machine that includes real-time release testing and can create commercial-ready tablets in just one day.”

“Continuous manufacturing is well suited for the production of precision medicines and those with breakthrough therapy designations where development timelines may be short and there are patients in urgent need of transformative new treatments,” officials said.

"This agreement enables Hovione to be at the forefront of an important evolution toward the use of continuous manufacturing and positions us as a reliable and innovative source for the production of new medicines," said Filipe Gaspar, VP R&D at Hovione. "Like Vertex, we view continuous manufacturing as an important scientific advance and an important advance for patients, as the technology will allow us to run manufacturing and process development in parallel with clinical studies to more rapidly bring new medicines to those who need them."

"Hovione and Vertex have been strong collaborators for more than a decade and share a commitment to innovative science," added Guy Villax, CEO of Hovione. "This agreement adds to a recently announced $24 million investment in our New Jersey facility. The entire expansion will double Hovione's development and manufacturing capacity at that site."

The new facility will include all facets of the continuous manufacturing process, including continuous blending, wet or dry granulation, fluid bed drying, tableting and coating operations. Spare capacity will be offered to third parties who are interested in manufacturing medicines through this process.

Exclusive Research